Regentys Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $15M

Regentys General Information

Description

Developer of tissue-engineered therapy designed to treat gastrointestinal disorders. The company develops a porcine-derived biological material that acts as a catalyst to stimulate the body to grow new, healthy tissue in place of diseased or damaged tissue and it mainly focuses on treatment for Inflammatory Bowel Disease, enabling patients to recover rare diseases.

Contact Information

Website
www.regentys.com
Formerly Known As
Asana Medical
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 6135 Northwest 167th Street
  • Suite E15
  • Miami Lakes, FL 33015
  • United States
+1 (844)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Generex Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 6135 Northwest 167th Street
  • Suite E15
  • Miami Lakes, FL 33015
  • United States
+1 (844)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regentys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 07-Jan-2019 $15M Completed Clinical Trials - General
3. Accelerator/Incubator Completed Clinical Trials - General
2. Early Stage VC (Series A) 07-Nov-2016 $1.45M $1.7M Completed Clinical Trials - General
1. Accelerator/Incubator 31-Oct-2014 $250K $250K Completed Clinical Trials - General
To view Regentys’s complete valuation and funding history, request access »

Regentys Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • Pending

  • Expiring in next 12 mo

Regentys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3500193-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016
US-20190184060-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016
CA-3034251-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016
EP-3500193-A4 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016
AU-2017313207-A1 Extracellular matrix for tissue reconstruction of mucosal tissue Inactive 19-Aug-2016 A61L27/3633
To view Regentys’s complete patent history, request access »

Regentys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regentys Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
43North Accelerator/Incubator Minority
University of Pittsburgh Innovation Institute Accelerator/Incubator
To view Regentys’s complete investors history, request access »

Ready to get started?

Request a free trial

Regentys FAQs

  • When was Regentys founded?

    Regentys was founded in 2013.

  • Where is Regentys headquartered?

    Regentys is headquartered in Miami Lakes, FL.

  • What is the size of Regentys?

    Regentys has 4 total employees.

  • What industry is Regentys in?

    Regentys’s primary industry is Drug Discovery.

  • Is Regentys a private or public company?

    Regentys is a Private company.

  • What is the current valuation of Regentys?

    The current valuation of Regentys is .

  • What is Regentys’s current revenue?

    The current revenue for Regentys is .

  • How much funding has Regentys raised over time?

    Regentys has raised $1.7M.

  • Who are Regentys’s investors?

    43North and University of Pittsburgh Innovation Institute have invested in Regentys.

  • When was Regentys acquired?

    Regentys was acquired on 07-Jan-2019.

  • Who acquired Regentys?

    Regentys was acquired by Generex Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »